Citation Impact
Citing Papers
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
Immunomodulatory properties of mesenchymal stromal cells
2007 Standout
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
2011
Effector Caspases and Leukemia
2011
Cancer statistics, 2024
2024 Standout
JAK2 Inhibitors: A Reality? A Hope?
2009
Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues
2009
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties
2011
A view on drug resistance in cancer
2019 StandoutNature
Curcumin, the Golden Spice From Indian Saffron, Is a Chemosensitizer and Radiosensitizer for Tumors and Chemoprotector and Radioprotector for Normal Organs
2010 Standout
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
2007
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
2012 Standout
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Activation of tyrosine kinases by mutation of the gatekeeper threonine
2008
Molecular monitoring of BCR–ABL as a guide to clinical management in chronic myeloid leukaemia
2005
Chronic myeloid leukaemia as a model of disease evolution in human cancer
2007
Regulation of chromatin by histone modifications
2011 Standout
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
2013 StandoutNobel
Mesenchymal stem cells in health and disease
2008 Standout
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
2008
T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia
2005
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
2007
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions
2021
Anticancer activities of histone deacetylase inhibitors
2006 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Targeting cancer with small molecule kinase inhibitors
2008 Standout
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Ubiquitylation and proteasomal degradation of the p21Cip1, p27Kip1and p57Kip2CDK inhibitors
2010
Caspase Functions in Cell Death and Disease
2013 Standout
Expansion of EPOR-negative macrophages besides erythroblasts by elevated EPOR signaling in erythrocytosis mouse models
2017
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms
2015
The essence of senescence: Figure 1.
2010 Standout
Investigational Janus kinase inhibitors
2013
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence
2010 Nature
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2011 Standout
Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution
2016
Oxidative Stress in Cancer
2020 Standout
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
2005 Standout
The cancer stem cell: premises, promises and challenges
2011 Standout
CAR-T cell therapy: current limitations and potential strategies
2021 Standout
Applying the discovery of the Philadelphia chromosome
2007
Genetics of therapy-related myelodysplasia and acute myeloid leukemia
2008
Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative
2007 StandoutNobel
The functions and regulation of the PTEN tumour suppressor
2012 Standout
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Cancer-related inflammation and treatment effectiveness
2014 Standout
Bispecific antibodies: a mechanistic review of the pipeline
2019
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
2007
Mechanisms of resistance to CAR T cell therapy
2019
Inhibiting Heat Shock Factor 1 in Cancer: A Unique Therapeutic Opportunity
2019
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
2006
β-Arrestin2 mediates the initiation and progression of myeloid leukemia
2012 StandoutNobel
2019
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
2004
Identification and transcriptome analysis of erythroblastic island macrophages
2019 StandoutNobel
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity
2017 StandoutNobel
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML
2006
Tumor Antigen Escape from CAR T-cell Therapy
2018
SGX393 inhibits the CML mutant Bcr-Abl T315I and preempts in vitro resistance when combined with nilotinib or dasatinib
2008
Modular repeat protein sculpting using rigid helical junctions
2020 StandoutNobel
New mutations and pathogenesis of myeloproliferative neoplasms
2011
The Myeloproliferative Disorders
2006
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering
2023 StandoutNobel
Works of Thomas G.P. Bumm being referenced
Characterization of Murine JAK2V617F-Positive Myeloproliferative Disease
2006
Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia
2008
Emergence of clonal cytogenetic abnormalities in Ph−cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority
2003
JAK2 V617F Mutation Induces a Myeloproliferative Disorder in Mice.
2005
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
2010
Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.
2004
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
2011
Absence of SKP2 expression attenuates BCR-ABL–induced myeloproliferative disease
2008
Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib
2006
Chromosomal Abnormalities in the Early Stem Cell Population of CML Patients in Complete Cytogenetic Remission.
2007
Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
2016
The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma
2012
TNF-alpha Plays a Crucial Role in the JAK2-V617F Induced Myeloproliferative Disorder.
2007